AstraZeneca buys cell therapy biotech in up to $1bn deal
AstraZeneca has struck a deal to acquire biotechnology EsoBiotec for up to $1bn, as the London-listed pharmaceuticals group expands its investments in cell therapies for treating cancer.
AstraZeneca goes in vivo, penning $1B deal for Belgian off-the-shelf cell therapy biotech
AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all outstanding equity of the Belgian biotech for a total consideration of $1 billion—split between an upfront payment of $425 million and up to $575 million in developmental and regulatory milestones.
M&A News: AstraZeneca Seals Belgian Firm EsoBiotec Deal to Boost Cell Therapy
Healthcare giant AstraZeneca (AZN) is set to buy Belgian firm EsoBiotec for up to $1 billion. The deal aims to speed up progress in cell
AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio
The deal includes the Belgian biotech’s vivo cell-therapy platform, which modifies immune cells within the patient’s body, potentially increasing access to treatment and reducing costs.
AstraZeneca to Buy Cell Therapy Company for Up to $1 Billion
AstraZeneca Plc agreed to buy the Belgian biotech EsoBiotec for as much as $1 billion in a deal that will see the British pharma giant further boost its cancer capabilities.
EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition
EsoBiotec SA, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical activity, today announced it has entered into a definitive agreement to be acquired by AstraZeneca (LSE/STO/Nasdaq: AZN).
Chinese drug maker Akeso hailed as biotech's 'DeepSeek moment' amid US competition
Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed ...
Bay Area biotech company once worth $2B guts staff, departing execs get $600K
Sutro Biopharma, a Bay Area oncology biotech company, is laying off around half its staff, switching up its leadership team ...
Unleased lab space. Plunging valuations. Layoffs. In Massachusetts, the biotech slump is taking its toll.
There are few signs the industry responsible for more than 115,000 Massachusetts jobs is pulling out of its four-year downswing.
STAT4d
Biotech raising $35 million to take a second stab at cancer drug from Bert Vogelstein’s lab
A new biotech is raising money to develop a drug believed to be capable of starving cancer cells, based on research out of a ...
It’s Phil King’s Regal against the shorts at biotech play Opthea
The high-profile stockpicker is the eye disorder treatment hopeful’s biggest shareholder. Ahead of the results of a crucial ...
Stocktwits on MSN10h
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week
The clinical-stage biopharmaceutical company saw the highest jump in retail interest after reporting positive topline data ...
15 Best Biotech Stocks to Buy According to Billionaires
In this article, we will be taking a look at the 15 best biotech stocks to buy according to billionaires. Although biotech ...
The Power Of Giving: How Offering Free Platforms Can Fuel Biotech Innovation
Offering free solutions can generate goodwill and strengthen relationships with both existing and potential customers. When a ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
HC Wainwright Boosts Earnings Estimates for Legend Biotech
Equities research analysts at HC Wainwright boosted their Q1 2025 earnings per share estimates for Legend Biotech in a ...
Investor's Business Daily on MSN2d
Stock Market Today: Dow Jones Gains 650 Points; This Biotech Name Pops 12% And Tops 3 IBD Lists (Live Coverage)
The Dow Jones and S&P 500 posted robust gains Friday afternoon. Nvidia led the Dow and Ulta topped the S&P 500 on the stock ...